Chris Hemsworth Co-Founded KINSYN, a Telehealth Platform Built Around Longevity
Chris Hemsworth co-founded KINSYN, a longevity platform that pairs telehealth visits with lab testing, supplements and prescriptions. Those prescriptions include compounded tirzepatide and semaglutide, and KINSYN’s own site notes compounded drugs are not FDA approved.

Your health data lives in five different places
Your sleep score is in one app, your bloodwork is in a patient portal and your supplement shelf keeps growing. Nobody is looking at all of it together. Chris Hemsworth says that’s the problem his new company wants to solve.
What actually happened
KINSYN launched on Nov. 12 as a personalized wellness platform co-founded by Hemsworth. The company says it brings physician-guided care, prescription therapies, supplements, lab testing and health data into one place. It’s designed to connect medical records from participating U.S. healthcare systems with biomarker, wearable and lifestyle data, and it uses its own AI to help providers shape recommendations.
“To me, longevity is not just about living longer. It’s about how you experience your life along the way,” Hemsworth said.
Members answer a few questions, get an evaluation from a licensed provider and can receive prescriptions when the provider decides they’re appropriate. Depending on a member’s needs, the announcement lists tirzepatide and semaglutide for metabolic health and weight management, injectables including NAD+, glutathione, sermorelin and B12, copper peptides and other skin and hair treatments, biomarker testing and a line of supplements. Matt Kawadler is CEO, Dr. Jonathan Schoeff is chief medical officer and an advisory board includes Stanford geneticist Dr. Michael Snyder.
The compounding part
KINSYN says its prescription therapies come from independent 503A compounding pharmacies that are licensed and inspected, that every prescription is up to the treating clinician and that no prescription is guaranteed. Its website adds that compounded medications are not FDA approved.
The FDA has a public page on compounded GLP-1s. It says compounded drugs are not FDA approved, which means the agency does not review them for safety, effectiveness or quality before they’re marketed. It also says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.
Our read: a medical practice with a movie star on the door
This is our read. Plenty of famous faces sell supplements. KINSYN is different because it’s a telehealth practice that prescribes, so the useful questions are the same ones you’d ask any online clinic. Who is prescribing, where do the drugs come from and what has the FDA said about them?
Reality check
Everything about KINSYN here comes from the company’s own announcement and website. Its GLP-1 options are compounded versions, not the FDA-approved brand-name drugs. A licensed clinician decides who qualifies, and KINSYN says not every patient will.
The close
One place for your labs, your wearable and your doctor sounds a lot tidier than five apps. Just read the fine print before that first consult.
Sources
Disclosure: WellWham has no affiliate links in this story.
Brand information: PR Newswire






